Protecting patient privacy when sharing patient-level data from clinical trials

Area of Science:

• Clinical trial data management
• Pharmaceutical research ethics
• Patient privacy in research

Background:

• Sharing patient-level clinical trial data is vital for scientific advancement and patient interests.
• Concerns exist regarding appropriate data preparation and sharing to maintain patient confidentiality.
• Data reduction techniques can mitigate privacy risks but must retain data utility for meaningful research.

Discussion:

• Recommendations emphasize de-identification methods like masking and generalization to protect patient privacy.
• Controlled access via legally binding data sharing agreements is essential, prohibiting data downloads or re-sharing.
• Secure data transfer methods, such as 'locked box' systems, enhance safeguards for third-party researchers.

Key Insights:

• De-identification is the data holder's responsibility to protect patient privacy.
• Data sharing agreements must include strict clauses on data usage and patient identification.
• Balancing data utility with privacy protection is paramount to avoid public health risks.

Outlook:

• Recommendations apply to all clinical trial data holders.
• Ongoing evaluation of evolving regulations, risk attitudes, and technologies is necessary.
• Further work is needed to identify and assess alternative data sharing possibilities.